NICE has approved the most expensive drug in the world, Alexion's Solaris for patients with atypical Hemolytic Uremic Syndrome (aHUS) after a previous rejection in January 2013.
HUS is a serious disease affecting about 200 people in England with an expected increase of 20 patients per year. The cost of treating one patient is more than half million dollars/year. The British government estimates a cost of about $ 95.5 million during the first year and with increasing population, the cost will rise to $135 million.
Such a costly approval may seem not to be in the interest of the general population, but the amount of documentations and research that goes into the whole process is very scientific and extensive. This is called the Real World Evidence Solutions (RWE).
The Turacoz Healthcare Solution’s team comprises of multidisciplinary professionals who are highly experienced in developing documents in real world evidence settings. Our RWE experts can provide information at every stage of a drug’s development by providing a thorough research, understanding of disease, treatment patterns and performance of the product. RWE solutions are the combination of the best available research (primary and secondary) evidence with clinical experience along with ascertaining patient needs.
After testing the efficacy and safety of a drug for clinical trials, the drug comes to the market. The health care stakeholders have to think beyond the randomized controlled trials (RCTs) for making the drug worthy for the payers: private insurance companies, government or individuals. In the broader sense only efficacy is not sufficient for the drug to perform well and contribute to the healthcare. Assessing effectiveness is an equally important to convince the stakeholders and policy makers to include the drug in the treatment guidelines and adapt for the state prescription. The RWE is the comprehensive understanding about the working of the drug outside the controlled clinical trial environment.
No comments:
Post a Comment